Background/Purpose: To compare the efficacy and safety of romozosumab (ROMO) and denosumab (DEN) in high-risk patients with glucocorticoid -induced osteoporosis (GIOP)

Methods: Adult patients (≥18 years) who were receiving daily prednisolone dose of ≥5mg/day for ≥12 months and had moderate/high risk of osteoporotic fracture (history of fragility fracture, DEXA T score ≤-2.5 [age≥40 years] or Z scores ≤-3.0 [age < 40 years] or high risk of 10-year major fracture estimated by FRAX) were included. Participants were given daily calcium/vitamin D and randomized to receive either ROMO (210mg SC monthly) or DEN (60mg SC every 6 months) for 12 months, followed by DEN (60mg every 6 months) for 12 more months in both arms. The primary end point was the change in bone mineral density (BMD) at the lumbar spine from baseline to month 12. Secondary end points included BMD change at the non-dominant hip and femoral neck at month 12, change in bone turnover markers, new vertebral fractures, change in BMD at the hip and spine at month 24 and adverse events.

Results: Of 70 patients recruited, 63(90%) completed the study (age 62.6±9.1 years; 96% women; 35 each assigned to ROMO or DEN). The mean prednisolone dose at entry was 6.6±3.5mg/day. Osteoporosis at spine/hip/femoral neck and a history of fragility fracture was present in 34(48.6%) and 35(50%) patients, respectively. Oral bisphosphonates were being used in 33(47%) patients prior to first dose of the study drugs. While the baseline demographics and osteoporosis risk factors were not significantly different between the two groups, ROMO-treated patients had lower hip/femoral neck BMD and serum vitamin D3 levels than those treated with DEN. At month 12, a significant increase in spine BMD was observed in both the ROMO (+7.3±4.5%; p< 0.001) and DEN (+2.3±3.1%; p< 0.001) groups of patients. The inter-group difference in spine BMD at month 12 was statistically significant after adjustment for baseline BMD values, age, sex, osteoporosis risk factors and the cumulative prednisolone doses in 12 months (p < 0.001). The corresponding increase in hip BMD were +1.6%±3.3% (p=0.01) in the ROMO group and +1.6%±2.6% (p=0.003) in the DEN group. No significant inter-group difference in hip BMD was observed. The increase in femoral neck BMD from baseline to month 12 was not significant in both groups. In DEN-treated patients, both serum CTX (-34.7±54.8%; p=0.002) and P1NP (-35.1±43.3%; p< 0.001) dropped significantly from baseline to month 12. However, in the ROMO group, a non-significant drop in CTX (-18.1±76.9%; p=0.18) but increase in P1NP (+1.7±70.3%; p=0.89) was observed. Only one new vertebral fracture developed in the ROMO group at 12m. The commonest adverse event (AE) was self-limiting injection site pain/redness, which was significantly more common in ROMO-treated patients. Post-injection musculoskeletal pain was reported in 2 patients in the ROMO and 3 patients in the DEN group. Mild hypocalcemia and hypercalcemia were observed in 2 DEN-treated patients. No serious AEs were reported.

Conclusion: Romosozumab was superior to denosumab in raising the spine BMD at month 12 in chronic GC users with high fracture risk. Both drugs were well-tolerated. Romosozumab may offer a new treatment option for GIOP in high-risk patients.

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/romosozumab-versus-denosumab-in-high-risk-patients-with-glucocorticoid-induced-osteoporosis-a-pilot-randomized-controlled-trial/